PainReform Ltd. logo
PainReform Ltd. PRFX
$ 0.47 -25.4%
report update icon

Quarterly report 2024-Q4
added 11-13-2026

PainReform Ltd. EBITDA | PRFX

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA PainReform Ltd.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-5.11 M -14.7 M -9.57 M -8.85 M -7.2 M -1.67 M -688 K -500 K - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-500 K -14.7 M -6.03 M

Quarterly EBITDA PainReform Ltd.

2025-Q4 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
-5.11 M -2.36 M -14.7 M -12.9 M -9.57 M -4.66 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
-2.36 M -14.7 M -8.21 M

References

  1. Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer EBITDA Price % 24h Market Cap Country
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
4.01 B $ 58.74 0.69 % $ 119 B usaUSA
Eiger BioPharmaceuticals Eiger BioPharmaceuticals
EIGR
-71.5 M - -9.21 % $ 2.55 M usaUSA
IGM Biosciences IGM Biosciences
IGMS
-199 M - - $ 76.9 M usaUSA
Merrimack Pharmaceuticals Merrimack Pharmaceuticals
MACK
-2.04 M - - $ 216 M usaUSA
Rubius Therapeutics Rubius Therapeutics
RUBY
-172 M - -33.55 % $ 7.81 M usaUSA
Mirati Therapeutics Mirati Therapeutics
MRTX
-757 M - - $ 3.3 B usaUSA
InVivo Therapeutics Holdings Corp. InVivo Therapeutics Holdings Corp.
NVIV
-10.6 M - -37.48 % $ 476 K usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
-27 M - -9.72 % $ 5.89 M usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
-124 M - 1.02 % $ 90.8 M britainBritain
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
21.9 M - - $ 154 M usaUSA
Oyster Point Pharma Oyster Point Pharma
OYST
-96.5 M - - $ 300 M usaUSA
Intercept Pharmaceuticals Intercept Pharmaceuticals
ICPT
-18.3 M - - $ 643 M usaUSA
Chinook Therapeutics Chinook Therapeutics
KDNY
-182 M - - $ 2.6 B usaUSA
Syros Pharmaceuticals Syros Pharmaceuticals
SYRS
-127 M - -8.44 % $ 3.4 M usaUSA
NanoViricides NanoViricides
NNVC
-7.79 M $ 1.15 -2.54 % $ 23.2 M usaUSA
GT Biopharma GT Biopharma
GTBP
-12.4 M $ 2.93 -7.86 % $ 16.2 M usaUSA
Zymeworks Zymeworks
ZYME
-212 M $ 26.41 -1.68 % $ 1.36 B canadaCanada
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
-35 M $ 0.84 16.41 % $ 50.4 M usaUSA
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
-38.5 M $ 0.51 1.61 % $ 5.64 M usaUSA
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
-602 M $ 50.7 -1.48 % $ 6.09 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
-144 M $ 9.03 -4.14 % $ 1.26 B franceFrance
Precision BioSciences Precision BioSciences
DTIL
-50.7 M $ 7.37 6.66 % $ 94.5 M usaUSA
Exelixis Exelixis
EXEL
901 M $ 64.59 -1.88 % $ 17.5 B usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
-6.28 M $ 13.09 -2.68 % $ 374 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
-48.6 M $ 0.85 -4.67 % $ 56.8 M usaUSA
BioNTech SE BioNTech SE
BNTX
-1.4 B $ 80.87 -0.63 % $ 19.5 B germanyGermany
Alkermes plc Alkermes plc
ALKS
281 M $ 44.89 -2.79 % $ 7.39 B irlandaIrlanda
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
203 M $ 68.6 -0.77 % $ 1.38 B usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
-11.6 M $ 0.11 -7.75 % $ 178 K usaUSA
AC Immune SA AC Immune SA
ACIU
-69.3 M $ 1.98 -7.28 % $ 199 M schweizSchweiz
Atara Biotherapeutics Atara Biotherapeutics
ATRA
38 M $ 6.51 2.6 % $ 81.7 M usaUSA
Allogene Therapeutics Allogene Therapeutics
ALLO
-197 M $ 0.63 -5.62 % $ 139 M usaUSA
Altimmune Altimmune
ALT
-94.4 M $ 1.33 -6.03 % $ 117 M usaUSA
AnaptysBio AnaptysBio
ANAB
32.3 M $ 46.65 -1.58 % $ 1.35 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-8.18 M - -1.52 % $ 24.7 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-136 M $ 252.39 -1.39 % $ 15.3 B danmarkDanmark
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
-73.2 M $ 7.42 -2.37 % $ 203 M israelIsrael
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
52.7 M $ 14.7 -1.28 % $ 1.98 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-262 M $ 0.91 -6.96 % $ 242 M britainBritain
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
-180 M $ 3.97 0.89 % $ 324 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
-166 M $ 129.32 -4.69 % $ 6.43 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
-518 M $ 75.96 -2.84 % $ 14.5 B usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
342 M $ 7.23 -1.3 % $ 1.52 B usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
-241 M $ 2.89 -5.25 % $ 200 M britainBritain
Benitec Biopharma Benitec Biopharma
BNTC
-51.1 M $ 7.95 -2.4 % $ 370 M usaUSA
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
-34.4 M $ 8.24 2.74 % $ 387 M usaUSA
Insmed Incorporated Insmed Incorporated
INSM
-1.24 B $ 141.06 -2.35 % $ 28.1 B usaUSA
Iovance Biotherapeutics Iovance Biotherapeutics
IOVA
-390 M $ 6.9 -5.61 % $ 2.47 M usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
-10.6 M $ 4.64 17.17 % $ 56.6 M israelIsrael
InMed Pharmaceuticals InMed Pharmaceuticals
INM
205 K $ 15.56 13.57 % $ 64.8 M canadaCanada